RSS-Feed abonnieren
PDF herunterladen
DOI: 10.5935/1806-6054.20190005
Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group: Neuroendocrine Tumors
Financial support: none to declare.
ABSTRACT
Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms with variable prognoses and clinical presentations. Therefore their therapeutic management is challenging, involving a real multidisciplinary approach composed of medical oncologists, surgeons, endocrinologists, nuclear medicine physicians and interventionist radiologists. Here in this article, we have summarized the studies that have changed (or are likely to influence) the clinical management of patients with NET in 2018: the new WHO pathology classification for pancreatic NET, the use of peptide receptor radionuclide therapy (PRRT) in G3 NET, re-treatment with PRRT, randomized data on the CapTem regimen and new data on carcinoid heart disease.
Publikationsverlauf
Eingereicht: 20. November 2018
Angenommen: 23. Januar 2019
Artikel online veröffentlicht:
07. März 2025
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
REFERENCES
- Öberg K, Knigge U, Kwekkeboom D, Perren A. on behalf of the ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (07) 124-130 .
- Rindi G, Arnold R, Bosman FT. et al Nomenclature and classification of neuroendocrine neoplasms of the digestive system. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. Lyon: IARC; 2010
- Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM. et al The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39 (05) 683-690
- Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R. et al Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012; 36 (02) 173-184
- Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A. et al DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331 (6021) 1199-1203
- Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D. et al Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas 2017; 46 (03) 302-305
- Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E, Kwekkeboom D. et al PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE inPatients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) - The Rotterdam Cohort. 15th Annual ENETS conference 2018; Abstract#2292
- Skovgaard D, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Zandee W. et al Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study. . 15th Annual ENETS conference 2018; Abstract#2072.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B. et al Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376 (02) 125-135
- Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M. et al Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors. . 15th Annual ENETS conference 2018;Abstract#2038.
- Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M. et al First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. J Clin Oncol 2018; 36 (15) 4099
- Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M. et al Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 2018; 36 (25) 2578-2584
- Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C. et al A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). 2018 ASCO Annual Meeting. Abstract 4004.
- Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. ecancer 2016; (10) 662
- Alves C, Mesquita M, Silva C, Soeiro M, Hajjar L, Riechelmann RP. High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease. ecancer 2018; (12) 879